United Therapeutics Financial Statements
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
United Therapeutics revenue and earnings
In fiscal 2025, United Therapeutics generated $3.18 billion in revenue, up 10.6% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $1.33 billion (+11.7% year over year), for a net margin of 41.9% versus a median of 37.6% in the prior 5 years. Gross margin was 87.9% (down from 89.2%) and operating margin 46.9%.
Diluted earnings per share came in at $27.86, up from $24.64. Over the last 5 fiscal years, UTHR's revenue has grown at a 16.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
United Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.18B | 2.88B | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B |
| Revenue growth (YoY) | +10.61% | +23.63% | +20.20% | +14.88% | +13.63% | +2.38% | -11.00% | -5.65% | +7.91% | +9.07% |
| Cost of Revenue | 384.40M | 309.70M | 257.50M | 151.60M | 122.50M | 108.10M | 117.60M | 198.70M | 105.70M | 72.70M |
| Gross Profit | 2.80B | 2.57B | 2.07B | 1.78B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B |
| Operating Expenses | 1.31B | 1.19B | 885.10M | 805.00M | 1.01B | 781.60M | 1.52B | 623.70M | 804.70M | 464.40M |
| Research & Development | 550.00M | 481.00M | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B | 357.90M | 264.60M | 147.60M |
| Selling, General & Admin | 755.80M | 709.70M | 477.10M | 482.10M | 467.00M | — | — | 265.80M | 330.10M | 316.80M |
| Operating Income | 1.49B | 1.38B | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M | 805.40M | 814.90M | 1.06B |
| Interest Expense | 19.50M | 42.90M | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M | 9.00M | 3.90M |
| Other Income (Expense) | 221.40M | 162.00M | 89.40M | -29.10M | 38.00M | 45.30M | 22.60M | -46.50M | -45.40M | -1.50M |
| Pretax Income | 1.71B | 1.54B | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M | 758.90M | 769.50M | 1.06B |
| Income Tax | 379.20M | 343.90M | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M | 169.70M | 351.60M | 346.50M |
| Net Income | 1.33B | 1.20B | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M |
| Net Income growth (YoY) | +11.68% | +21.35% | +35.40% | +52.86% | -7.58% | — | -117.74% | +40.99% | -41.45% | +9.53% |
| EPS (Basic) | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 |
| EPS (Diluted) | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 |
| Shares Outstanding (Basic) | 44.30M | 45.20M | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M | 43.50M | 44.00M | 43.80M |
| Shares Outstanding (Diluted) | 47.90M | 48.50M | 49.70M | 48.50M | 47.30M | 44.60M | 43.80M | 44.00M | 44.90M | 46.80M |
| EBITDA | 1.58B | 1.45B | 1.24B | 1.03B | 605.80M | 643.50M | -141.70M | 841.30M | 845.90M | 1.09B |
| Gross Margin | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% |
| Operating Margin | 46.89% | 47.86% | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% |
| Net Margin | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% |
This table shows 10 annual periods of United Therapeutics's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow UTHR's reporting calendar. What is a income statement?